Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

GordoHLYK13 Aug. 2 at 8:59 PM

$IGC https://youtu.be/gDDhi_U0ZWQ?is=_PgNotWj9U3p8bLY Easy money!! Why not invest and take a chance $MRNA $PFE Ram Mukunda continues to show strong, steady leadership—clear communication, disciplined execution, respected partnerships, and a sharp focus on solving major unmet needs in Alzheimer’s. Quiet confidence backed by results.

0 · Reply

JustBen47 Aug. 1 at 11:27 PM

$IGC need some bullish news

0 · Reply

_jaydub_ Jul. 31 at 3:36 PM

$IGC got share count to 51789! Right at .2567

2 · Reply

Deelam Jul. 30 at 8:54 PM

$IGC Same thing for every bullish catalyst from the last couple months. Does nothing to the SP. No algos on this one. No institutional buyin, not much short interest. It's just a boring stock waiting for topline data.

0 · Reply

angel6 Jul. 30 at 8:37 PM

$IGC why the price drops if the news is positive It doesn’t make sense

0 · Reply

NewsAndFilings Jul. 30 at 12:24 PM

Yesterday's Recap: $BRQL: drone logistics deal for healthcare, govt, commercial $TERS: names Paul Vanderpool senior advisor to PolyCycle $VMHG: GUTSI™ mineral platform expands across beverages & nutrition $IGC: weighs recovery after verdict revives 2018 short-campaign scrutiny

0 · Reply

CatHerder69 Jul. 30 at 4:04 AM

$IGC anytime you want to do something

0 · Reply

MsGrumpy Jul. 29 at 8:22 PM

$IGC Federal jury convicts Andrew Left of securities fraud in the 2018 short campaign against IGC Pharma https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-evaluates-potential-recovery-options-as-federal-jury-verdict-brings-renewe-1197865

0 · Reply

RocketQueen Jul. 29 at 7:10 PM

$IGC plan to load up more soon.

0 · Reply

myusername123 Jul. 29 at 6:35 PM

$IGC suddenly a 9% drop today. interesting.

2 · Reply

IGC Pharma evaluates potential civil remedies following federal jury verdict

Jul 29, 2026, 8:30 AM EDT - 4 days ago

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

Jul 13, 2026, 7:00 AM EDT - 20 days ago

IGC Pharma Slides: Investor presentation

Jul 9, 2026, 9:00 AM EDT - 24 days ago

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

2026-07-07T13:26:29.000Z - 26 days ago

IGC Pharma CEO, principal financial officer purchase over $1.15M of stock

Jul 7, 2026, 9:00 AM EDT - 26 days ago

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

2026-06-23T16:59:03.000Z - 5 weeks ago

IGC Pharma announced beta version of Agentic Harmonization Assistant

Jun 23, 2026, 8:30 AM EDT - 5 weeks ago

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

2026-06-11T12:43:47.000Z - 7 weeks ago

IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial

Jun 11, 2026, 8:30 AM EDT - 7 weeks ago

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Jun 9, 2026, 8:30 AM EDT - 7 weeks ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

2026-06-02T15:20:34.000Z - 2 months ago

IGC Pharma adds Mount Sinai clinical site as CALMA trial advances

Jun 2, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

May 19, 2026, 5:30 PM EDT - 2 months ago

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

2026-05-15T13:00:12.000Z - 2 months ago

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

May 15, 2026, 8:00 AM EDT - 2 months ago

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

May 15, 2026, 8:00 AM EDT - 2 months ago

IGC Pharma Quarterly report: Q1 2026

Apr 28, 2026, 12:15 PM EDT - 3 months ago

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

2026-04-22T13:29:55.000Z - 3 months ago

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

Apr 22, 2026, 8:30 AM EDT - 3 months ago

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

2026-04-20T14:17:51.000Z - 3 months ago

IGC Pharma secures Colombian authorization for psilocybin research

Apr 20, 2026, 8:30 AM EDT - 3 months ago

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

2026-04-14T12:36:26.000Z - 3 months ago

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

Apr 14, 2026, 8:30 AM EDT - 3 months ago

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 8, 2026, 12:45 PM EDT - 4 months ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

2026-04-07T12:50:45.000Z - 4 months ago

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

Apr 7, 2026, 8:00 AM EDT - 4 months ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

2026-03-30T12:38:30.000Z - 4 months ago

IGC Pharma enters national media partnership with New to The Street

Mar 30, 2026, 8:00 AM EDT - 4 months ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

2026-03-25T12:20:15.000Z - 4 months ago

IGC Pharma, New to The Street launch 12-part national media partnership

2026-03-19T13:12:05.000Z - 4 months ago

IGC Pharma reports 9-month revenue $969K

Mar 19, 2026, 9:00 AM EDT - 4 months ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

2026-03-18T13:10:59.000Z - 4 months ago

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

Mar 18, 2026, 9:00 AM EDT - 4 months ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Feb 26, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 24, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 23, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 18, 2026, 1:00 PM EST - 5 months ago

IGC Pharma Transcript: Status update

Feb 17, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 12, 2026, 8:30 AM EST - 6 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 10, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 9, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 2, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Jan 22, 2026, 9:00 AM EST - 6 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 12, 2026, 9:00 AM EST - 7 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 6, 2026, 8:00 AM EST - 7 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 5, 2026, 9:00 AM EST - 7 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Dec 19, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 3, 2025, 7:00 AM EST - 8 months ago

IGC Pharma Registration statement: Registration Filing

Dec 2, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 11:00 AM EST - 9 months ago

IGC Pharma Earnings Call Transcript: Q3 2025

Nov 17, 2025, 11:00 AM EST - 9 months ago

IGC Pharma Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 7:00 AM EST - 9 months ago

IGC Pharma Registration statement: Registration Filing

Nov 13, 2025, 9:00 AM EST - 9 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 9 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 9 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 10 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 1 year ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

GordoHLYK13 Aug. 2 at 8:59 PM

0 · Reply

JustBen47 Aug. 1 at 11:27 PM

$IGC need some bullish news

0 · Reply

_jaydub_ Jul. 31 at 3:36 PM

$IGC got share count to 51789! Right at .2567

2 · Reply

Deelam Jul. 30 at 8:54 PM

0 · Reply

angel6 Jul. 30 at 8:37 PM

$IGC why the price drops if the news is positive It doesn’t make sense

0 · Reply

NewsAndFilings Jul. 30 at 12:24 PM

0 · Reply

CatHerder69 Jul. 30 at 4:04 AM

$IGC anytime you want to do something

0 · Reply

MsGrumpy Jul. 29 at 8:22 PM

0 · Reply

RocketQueen Jul. 29 at 7:10 PM

$IGC plan to load up more soon.

0 · Reply

myusername123 Jul. 29 at 6:35 PM

$IGC suddenly a 9% drop today. interesting.

2 · Reply

Giants67 Jul. 29 at 5:05 PM

$IGC IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-evaluates-potential-recovery-options-as-federal-jury-verdict-brings-renewe-1197865

0 · Reply

NewsAndFilings Jul. 29 at 1:10 PM

$IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-evaluates-potential-recovery-options-as-federal-jury-verdict-brings-renewe-1197865

0 · Reply

_jaydub_ Jul. 28 at 4:52 PM

$IGC added 27500 today! On the ask

1 · Reply

GordoHLYK13 Jul. 28 at 8:17 AM

$IGC 9 out of 10 patients improved in a new THC/CBD dementia study. The Alzheimer’s treatment landscape is changing—and IGC is in the game. 🚀 $PFE $MRNA

0 · Reply

GordoHLYK13 Jul. 28 at 8:13 AM

$IGC The Real "5 Billion Dollar Question" The real multibillion-dollar question isn't whether melatonin allows for less THC than pure cannabis—it’s whether IGC-AD1 can reliably deliver clinically meaningful agitation relief without an FDA Black Box Warning. If the upcoming Phase 2 data confirms that this combination outperforms placebo while maintaining its clean safety profile, IGC will have validated a non-antipsychotic, non-antidepressant solution in a market desperate for safe alternatives. That statistical separation from placebo is the actual catalyst that unlocks the drug's full commercial value. $PFE $MRNA

0 · Reply

Deelam Jul. 27 at 10:42 PM

$IGC I don't want to be contrarian, but this isn't really the question IGC is trying to answer. They're trying to prove that adding melatonin can reduce the amount of THC needed as to cause fewer or no side effects but still be as effective as pure THC. That's the 5 billion dollar question.

1 · Reply

distanceswimmer Jul. 26 at 5:21 PM

$IGC

0 · Reply

GordoHLYK13 Jul. 22 at 11:53 AM

$IGC CEO Ram Mukunda laid out a clear roadmap: Phase 2 CALMA enrollment wraps by late Aug./early Sept., final dosing by October, and the highly anticipated topline data is expected in Q4 2026. Meanwhile, IGC’s AI platforms continue advancing toward commercialization. Multiple catalysts are lining up, and a successful CALMA readout could support a $5+ price target. 🚀 I’m not selling!!!!! https://youtu.be/gDDhi_U0ZWQ?is=xi0mb-zmBGaop4h7

0 · Reply

_jaydub_ Jul. 21 at 2:46 PM

$IGC Vol is drying up

1 · Reply

GordoHLYK13 Jul. 18 at 6:26 PM

$IGC easy money $IGC is firing on all cylinders. Phase 2 CALMA is fully enrolled and advancing toward topline data, while its AI platform is showing the potential to transform clinical trial efficiency. CEO Ram Mukunda and the PFO backed that vision by converting over $1.15M into common stock at market price—a strong sign of insider conviction. Add global exposure at AAIC 2026 and a growing investor outreach campaign, and IGC is entering one of its biggest potential catalyst periods yet. 🚀 $MRNA $PFE

0 · Reply

RocketQueen Jul. 18 at 4:27 AM

$IGC In case you missed it, insider buying activity: https://igcpharma.com/igc-pharma-ceo-and-principal-financial-officer-purchase-more-than-1-15-million-of-common-stock-directly-from-the-company/

0 · Reply

Rolfthewild Jul. 17 at 6:10 PM

$IGC Dippidy dipp. Bought the dip.

0 · Reply

Market Cap	24.92M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	184,800
Avg Vol	562,324
Day's Range	N/A - N/A
Shares Out	100.09M
Stochastic %K	35%
Beta	0.45
Analysts	Sell
Price Target	$4.25